Safety under the regulatory spotlight — 206 documents in 90 days

81 documents in the last 30 days alone

This concentration of activity around safety may indicate a tightening cycle, particularly if the recent documents are skewed toward new expectations, signal detection, or postmarketing risk management rather than routine clarifications. Sponsors should consider that regulators may be sharpening their focus on benefit-risk justification and the operational quality of safety surveillance, so companies with safety programs should watch for shifts in pharmacovigilance standards, data integration expectations, and any language that could signal more rigorous scrutiny of emerging safety signals.